CD19 and CD32b differentially regulate human B cell responsiveness

Journal of Immunology

Volumn 192, Issue 4, 2014, Pages 1480-1490

  Karnell, Jodi L ^a   Dimasi, Nazzareno ^a   Karnell III, Fredrick G ^a   Fleming, Ryan ^a   Kuta, Ellen ^a   Wilson, Mildred ^b   Wu, Herren ^a   Gao, Changshou ^a   Herbst, Ronald ^a   Ettinger, Rachel ^a  

^a MEDIMMUNE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD19 ANTIBODY; CD19 ANTIGEN; CD4 ANTIGEN; FC RECEPTOR IIB; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 21; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; INHIBITION KINETICS; LYMPHOCYTE FUNCTION; MALE; MIDDLE AGED; PLASMA CELL; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIBODIES; ANTIGENS, CD19; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL DIFFERENTIATION; CELLS, CULTURED; CROSS-LINKING REAGENTS; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKINS; LYMPHOCYTE ACTIVATION; PLASMA CELLS; PROTEIN BINDING; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, IGG; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84896719168     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301361     Document Type: Article

References (48)

1. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
2. Amigorena, S., C. Bonnerot, J. R. Drake, D. Choquet, W. Hunziker, J. G. Guillet, P. Webster, C. Sautes, I. Mellman, and W. H. Fridman. 1992. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256: 1808-1812.
3. Muta, T., T. Kurosaki, Z. Misulovin, M. Sanchez, M. C. Nussenzweig, and J. V. Ravetch. 1994. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 369: 340.
4. Fong, D. C., A. Brauweiler, S. A. Minskoff, P. Bruhns, I. Tamir, I. Mellman, M. Daeron, and J. C. Cambier. 2000. Mutational analysis reveals multiple distinct sites within Fc gamma receptor IIB that function in inhibitory signaling. J. Immunol. 165: 4453-4462.
5. Takai, T., M. Ono, M. Hikida, H. Ohmori, and J. V. Ravetch. 1996. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 379: 346-349.
6. McGaha, T. L., M. C. Karlsson, and J. V. Ravetch. 2008. FcgammaRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. J. Immunol. 180: 5670-5679.
7. Brownlie, R. J., K. E. Lawlor, H. A. Niederer, A. J. Cutler, Z. Xiang, M. R. Clatworthy, R. A. Floto, D. R. Greaves, P. A. Lyons, and K. G. Smith. 2008. Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J. Exp. Med. 205: 883-895.
8. Chen, J. Y., C. M. Wang, C. C. Ma, S. F. Luo, J. C. Edberg, R. P. Kimberly, and J. Wu. 2006. Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients. Arthritis Rheum. 54: 3908-3917.
9. Floto, R. A., M. R. Clatworthy, K. R. Heilbronn, D. R. Rosner, P. A. MacAry, A. Rankin, P. J. Lehner, W. H. Ouwehand, J. M. Allen, N. A. Watkins, and K. G. Smith. 2005. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat. Med. 11: 1056-1058.
10. Haas, K. M., and T. F. Tedder. 2005. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity. Adv. Exp. Med. Biol. 560: 125-139.
11. Tedder, T. F., M. Inaoki, and S. Sato. 1997. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6: 107-118.
12. Buhl, A. M., and J. C. Cambier. 1999. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase. J. Immunol. 162: 4438-4446.
13. Li, X., D. Sandoval, L. Freeberg, and R. H. Carter. 1997. Role of CD19 tyrosine 391 in synergistic activation of B lymphocytes by coligation of CD19 and membrane Ig. J. Immunol. 158: 5649-5657.
14. Wang, Y., S. R. Brooks, X. Li, A. N. Anzelon, R. C. Rickert, and R. H. Carter. 2002. The physiologic role of CD19 cytoplasmic tyrosines. Immunity 17: 501-514.
15. Fujimoto, M., Y. Fujimoto, J. C. Poe, P. J. Jansen, C. A. Lowell, A. L. DeFranco, and T. F. Tedder. 2000. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 13: 47-57.
16. Engel, P., L. J. Zhou, D. C. Ord, S. Sato, B. Koller, and T. F. Tedder. 1995. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3: 39-50.
17. Rickert, R. C., K. Rajewsky, and J. Roes. 1995. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376: 352-355.
18. van Zelm, M. C., I. Reisli, M. van der Burg, D. Castaño, C. J. van Noesel, M. J. van Tol, C. Woellner, B. Grimbacher, P. J. Patiño, J. J. van Dongen, and J. L. Franco. 2006. An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354: 1901-1912.
19. Sato, S., M. Hasegawa, M. Fujimoto, T. F. Tedder, and K. Takehara. 2000. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J. Immunol. 165: 6635-6643.
20. Tsuchiya, N., K. Kuroki, M. Fujimoto, Y. Murakami, T. F. Tedder, K. Tokunaga, K. Takehara, and S. Sato. 2004. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum. 50: 4002-4007.
21. Mei, H. E., S. Schmidt, and T. Dörner. 2012. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res. Ther. 14(Suppl. 5): S1.
22. Barrett, T. B., G. L. Shu, K. E. Draves, A. Pezzutto, and E. A. Clark. 1990. Signaling through CD19, Fc receptors or transforming growth factor-beta: each inhibits the activation of resting human B cells differently. Eur. J. Immunol. 20: 1053-1059.
23. Rigley, K. P., and R. E. Callard. 1991. Inhibition of B cell proliferation with anti-CD19 monoclonal antibodies: anti-CD19 antibodies do not interfere with early signaling events triggered by anti-IgM or interleukin 4. Eur. J. Immunol. 21: 535-540.
24. Johnson, S., S. Burke, L. Huang, S. Gorlatov, H. Li, W. Wang, W. Zhang, N. Tuaillon, J. Rainey, B. Barat, et al. 2010. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J. Mol. Biol. 399: 436-449.
25. Herbst, R., Y. Wang, S. Gallagher, N. Mittereder, E. Kuta, M. Damschroder, R. Woods, D. C. Rowe, L. Cheng, K. Cook, et al. 2010. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. [Published erratum appears in 2011 J. Pharmacol. Exp. Ther. 336: 294.] J. Pharmacol. Exp. Ther. 335: 213-222.
26. Rankin, C. T., M. C. Veri, S. Gorlatov, N. Tuaillon, S. Burke, L. Huang, H. D. Inzunza, H. Li, S. Thomas, S. Johnson, et al. 2006. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 108: 2384-2391.
27. Oganesyan, V., C. Gao, L. Shirinian, H. Wu, and W. F. Dall'Acqua. 2008. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. D Biol. Crystallogr. 64: 700-704.
28. Karnell, J. L., F. G. Karnell, III, G. L. Stephens, B. Rajan, C. Morehouse, Y. Li, B. Swerdlow, M. Wilson, R. Goldbach-Mansky, C. Groves, et al. 2011. Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J. Immunol. 187: 3603-3612.
29. Crouch, S. P., R. Kozlowski, K. J. Slater, and J. Fletcher. 1993. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J. Immunol. Methods 160: 81-88.
30. Xiang, Z., A. J. Cutler, R. J. Brownlie, K. Fairfax, K. E. Lawlor, E. Severinson, E. U. Walker, R. A. Manz, D. M. Tarlinton, and K. G. Smith. 2007. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8: 419-429.
31. Ettinger, R., G. P. Sims, A. M. Fairhurst, R. Robbins, Y. S. da Silva, R. Spolski, W. J. Leonard, and P. E. Lipsky. 2005. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol. 175: 7867-7879.
32. Yanaba, K., J. D. Bouaziz, T. Matsushita, C. M. Magro, E. W. St. Clair, and T. F. Tedder. 2008. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223: 284-299.
33. + T cell-B cell collaboration. J. Immunol. 179: 5886-5896.
34. Yazawa, N., M. Fujimoto, S. Sato, K. Miyake, N. Asano, Y. Nagai, O. Takeuchi, K. Takeda, H. Okochi, S. Akira, et al. 2003. CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood 102: 1374-1380.
35. Yoshizaki, A., Y. Iwata, K. Komura, F. Ogawa, T. Hara, E. Muroi, M. Takenaka, K. Shimizu, M. Hasegawa, M. Fujimoto, et al. 2008. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am. J. Pathol. 172: 1650-1663.
36. Veri, M. C., S. Burke, L. Huang, H. Li, S. Gorlatov, N. Tuaillon, G. J. Rainey, V. Ciccarone, T. Zhang, K. Shah, et al. 2010. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum. 62: 1933-1943.
37. Horton, H. M., S. Y. Chu, E. C. Ortiz, E. Pong, S. Cemerski, I. W. Leung, N. Jacob, J. Zalevsky, J. R. Desjarlais, W. Stohl, and D. E. Szymkowski. 2011. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J. Immunol. 186: 4223-4233.
38. Chu, S. Y., I. Vostiar, S. Karki, G. L. Moore, G. A. Lazar, E. Pong, P. F. Joyce, D. E. Szymkowski, and J. R. Desjarlais. 2008. Inhibition of B cell receptormediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol. Immunol. 45: 3926-3933.
39. Hepburn, A. L., J. C. Mason, and K. A. Davies. 2004. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis. Rheumatology (Oxford) 43: 547-554.
40. Stewart-Akers, A. M., A. Cunningham, M. C. Wasko, and P. A. Morel. 2004. Fc gamma R expression on NK cells influences disease severity in rheumatoid arthritis. Genes Immun. 5: 521-529.
41. Wijngaarden, S., J. G. van de Winkel, K. M. Jacobs, J. W. Bijlsma, F. P. Lafeber, and J. A. van Roon. 2004. A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum. 50: 3878-3887.
42. Mackay, M., A. Stanevsky, T. Wang, C. Aranow, M. Li, S. Koenig, J. V. Ravetch, and B. Diamond. 2006. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J. Exp. Med. 203: 2157-2164.
43. Enyedy, E. J., J. P. Mitchell, M. P. Nambiar, and G. C. Tsokos. 2001. Defective FcgammaRIIb1 signaling contributes to enhanced calcium response in B cells from patients with systemic lupus erythematosus. Clin. Immunol. 101: 130-135.
44. Kono, H., C. Kyogoku, T. Suzuki, N. Tsuchiya, H. Honda, K. Yamamoto, K. Tokunaga, and Z. Honda. 2005. FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. 14: 2881-2892.
45. Kyogoku, C., H. M. Dijstelbloem, N. Tsuchiya, Y. Hatta, H. Kato, A. Yamaguchi, T. Fukazawa, M. D. Jansen, H. Hashimoto, J. G. van de Winkel, et al. 2002. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 46: 1242-1254.
46. Siriboonrit, U., N. Tsuchiya, M. Sirikong, C. Kyogoku, S. Bejrachandra, P. Suthipinittharm, K. Luangtrakool, D. Srinak, R. Thongpradit, K. Fujiwara, et al. 2003. Association of Fcgamma receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais. Tissue Antigens 61: 374-383.
47. Rodriguez-Bayona, B., A. Ramos-Amaya, J. Bernal, A. Campos-Caro, and J. A. Brieva. 2012. Cutting edge: IL-21 derived from human follicular helper T cells acts as a survival factor for secondary lymphoid organ, but not for bone marrow, plasma cells. J. Immunol. 188: 1578-1581.
48. Sfikakis, P. P., J. N. Boletis, S. Lionaki, V. Vigklis, K. G. Fragiadaki, A. Iniotaki, and H. M. Moutsopoulos. 2005. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52: 501-513.